Pfizer is in advanced talks to acquire U.S. cancer drug company Medivation for close to $14 billion, as it seeks to boost its oncology portfolio, people familiar with the matter said on Sunday.
Pfizer has agreed to pay a little more than $80 per share for Medivation, one of the people said, a substantial premium to the $52.50 offer for Medivation that France's Sanofi SA made in April, which eventually resulted in the company putting itself up for sale. Medivation shares ended trading in Ne...
00:02 AT&T Aims for an Empire in Merger Talks With Time Warner5
23:06 AT&T discussed takeover in meetings with Time Warner: Bloomberg
16:51 Scottrade Sale Nearly Doubles Owner’s Wealth to $4 Billion8
21:31 Time Warner jumps after hours on report it could sell for $110 per share to AT&T1